Sarepta Therapeutics' Long-Term Potential Intact Despite Near-Term Stock Weakness

I've been writing for Seeking Alpha since 2017 with a focus on healthcare and technology investments. With a background as a Registered Nurse, I analyze biotech stocks by evaluating clinical data, treatment guidelines, and market dynamics. My MBA provided a foundation of financial theory, allowing me to expand into technology investments, where I focus on identifying key valuation drivers and using DCF modeling for scenario-based forecasts. My thinking is influenced by books such as "Superforecasting" and " ...